Positive Predictive Value and Correct Detection Rate of ^{18}F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard

Maythinee Chantadisai[*1,2], Gabriel Buschner[*1], Markus Krönke[1], Isabel Rauscher[1], Thomas Langbein[1], Stephan G. Nekolla[1], Kilian Schiller[3], Matthias M. Heck[4], Tobias Maurer[4,5], Alexander Wurzer[5], Hans-Juergen Wester[6], Calogero D'Alessandria[1], Wolfgang Weber[1], and Matthias Eiber[1]

[1]School of Medicine, Department of Nuclear Medicine, Technical University Munich, Munich, Germany; [2]Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand; [3]School of Medicine, Department of Radiation Oncology, Technical University Munich, Munich, Germany; [4]School of Medicine, Department of Urology, Technical University Munich, Munich, Germany; [5]Martini-Klinik and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and [6]Technical University of Munich, Chair of Radiopharmacy

The objective of this retrospective study was to assess the detection rate (DR), positive predictive value (PPV), and correct detection rate (CDR) of ^{18}F-rhPSMA-7 PET/CT in biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) using composite validation. **Methods:** ^{18}F-rhPSMA-7 PET/CT scans of patients with BCR between July 2017 and June 2018 were retrospectively reviewed. All suspicious lesions were recorded. The reference standard was histopathology or combinations of histopathology, imaging, or prostate-specific antigen (PSA) follow up, defined as composite reference standard. DR was calculated as the proportion of PSMA PET—positive patients to all patients independent of the reference standard, whereas the CDR was the percentage of patients who had at least 1 true-positive PSMA PET lesion localized that corresponded with the reference standard. The PPV was defined as the proportion of patients who had true-positive to all positive findings. The correlation between DR and patient characteristics was evaluated. **Results:** A total of 532 patients with a median PSA level of 0.97 ng/mL (interquartile range: 0.41–2.46 ng/mL) were included. Of these, 162 patients had composite follow-up at a median duration of 5.6 mo (range: 1.1–14.2 mo). The proportion of patients who had no lesion visualized on PET/CT, localized disease, and any distant metastases (M1) were 20%, 43%, and 37%, respectively. PET DR among all patients was 80%. On a per-patient basis, the PPV of ^{18}F-rhPSMA-7 PET/CT in the composite cohort was 88%, and the CDR was 70%. The PPV in the histopathology-proven cohort was 91%, and the CDR in this subgroup was 73%. In patients with PSA levels $\geq$ 1 ng/mL the DR and PPV were 90% and 91%, respectively, resulting in a CDR of 82%. In patients with PSA levels < 1 ng/mL, the DR and PPV were 69% and 85%, respectively, resulting in a CDR of 59%. There was a significant positive correlation between ^{18}F-rhPSMA-7 PET/CT detection efficacy and stratified PSA levels ($P = 0.005$), as well as PSA nadir after prostatectomy ($P < 0.001$). **Conclusion:** ^{18}F-rhPSMA-7 PET/CT offers high PPV in BCR after RP. Its CDR is dependent on the prescan PSA value with excellent CDR in patients with PSA $\geq$ 1 ng/mL.

Biochemical recurrence (BCR) of prostate cancer (PCa) after initial curative treatment is frequent, especially in patients with high-risk disease. Early and localized detection of recurrent PCa is essential to plan further local or systemic treatment. Early initiation of localized salvage therapy in localized disease lowers the risk of metastasis and decreases PCa-specific mortality (*1,2*). Failure of salvage treatments is known to be related to incomplete tumor localization and therefore inadequate treatment strategies (*1*).

Radiolabeled-prostate-specific membrane antigen (PSMA) PET/CT imaging is currently regarded as the most sensitive and precise imaging modality for localization of BCR of PCa (*3,4*). Multiple prospective and retrospective studies and recent meta-analyses indicate a high accuracy of ^{68}Ga-PSMA-11 (*5–8*). Currently, ^{18}F-labeled PSMA-ligands are increasingly being evaluated given their advantages such as longer half-life and with this facilitated large-scale production for broad distribution. Further they offer a potentially higher image resolution due to lower positron range when compared with ^{68}Ga-labeled agents. They showed excellent diagnostic performance in men with BCR of PCa (*9–11*), but the clinical impact is yet to be explored (*12*). ^{18}F-rhPSMA-7 is one of a new class of radiohybrid (rh) PSMA-ligands that provides the unique opportunity of both fluorination and chelation using radiometals (^{68}Ga, ^{177}Lu-177).

Data on detection rate (DR) of ^{18}F-rhPSMA-7 in BCR after radical prostatectomy (RP) have recently been published (*11*). However, the report is lacking information on the validation of positive lesions, which is important to assess the diagnostic accuracy.

Our aim was to establish the positive predictive value (PPV) and the correct detection rate (CDR) validated by a standard of truth for ^{18}F-rhPSMA-7 PET/CT in an expanded cohort of patients with BCR after radical prostatectomy.

TABLE 1
Patient Characteristics

| Characteristic | All patients (n = 532) | Efficacy cohort | |
		Composite cohort (n = 162)	Histopathologic cohort (n = 22)
Median age (y)	71 (range, 48–89)	71 (range, 51–90)	68 (range, 56–82)
PCa therapy			
Local salvage therapy	121 (23)	29 (18)	7 (32)
Androgen deprivation therapy	58 (11)	27 (17)	0 (0)
Multiple treatment	115 (22)	53 (33)	8 (36)
Others	2 (0)	2 (1)	0 (0)
Not available/no prior treatment	236 (44)	51 (31)	7 (32)
Time between surgery and PSMA PET (y)			
Median	4.7 (range, 0–28)	4.0 (range, 0–23)	3 (range, 1–23)
<4.7	264 (50)	86 (53)	12 (55)
≥4.7	267 (50)	74 (46)	9 (41)
Not available	1 (0)	2 (1)	1 (5)
Primary T stage			
≤T2	152 (29)	41 (25)	11 (50)
≥T3	288 (54)	99 (61)	7 (32)
Not available	92 (17)	22 (14)	4 (18)
Pathologic regional LN staging (pN)			
pN0	296 (56)	86 (53)	11 (50)
pN1	118 (22)	46 (28)	6 (27)
pNx	118 (22)	30 (19)	5 (23)
Gleason score/ISUP–grade group			
≤7/≤3	155 (29)	56 (35)	11 (50)
≥8/≥4	116 (22)	46 (28)	8 (36)
Not available	261 (49)	60 (37)	3 (14)
PSA nadir after prostatectomy (ng/mL)*			
Median	0.1 (range, 0–200)	0.01 (range, 0–19)	1.19 (range, 0–132)
<0.1	135 (25)	12 (7)	3 (14)
≥0.1	86 (16)	8 (5)	0 (0)
Not available	311 (58)	142 (88)	19 (86)
Median PSA at the time of PET/CT (ng/mL)	0.97 (range, 0–400)	1.19 (range, 0–132)	0.84 (range, 0.19–11.6)
dtPSA (mo)†			
Median	6.84 (range, 1–179)	5.02 (range, 1–33)	4.06 (range, 1–9)
<6.8	59 (11)	27 (17)	4 (18)
≥6.8	62 (12)	14 (9)	2 (9)
Not available	411 (77)	121 (75)	16 (73)

*In accordance with the study by Bianchi et al. (23).

†In accordance with the study by Pound et al. (24), change in therapy not excluded.

Data in parentheses are percentages, unless otherwise indicated.

ISUP = International Society of Urological Pathology.

MATERIALS AND METHODS

Patients

A total number of 532 patients who underwent a clinically indicated ^{18}F-rhPSMA-7 PET/CT for BCR between July 2017 and June 2018 were retrospectively evaluated. A subcohort of the patients in this work was already included in a prior analysis (11). Patients who have undergone RP either as a primary treatment or a salvage treatment after external-beam radiation therapy with curative intent were included. Clinical data are presented in Table 1. The median PSA level at the time of ^{18}F-rhPSMA-7 PET/CT was 0.97 ng/mL (interquartile range [IQR]: 0.41–2.46 ng/mL).

FIGURE 1. Flow diagram for efficacy cohort with composite validation.

FIGURE 2. True-positive pelvic lymph nodes metastasis. Axial fused PET/CT (A) and CT (B) revealed 2 subcentimeter lymph nodes with ^{18}F-rhPSMA-7 uptake (SUV$_{max}$ = 8.7) at left presacral region. Largest one measured about 6.3 mm in short-axis diameter (arrow). After external-beam radiation, follow-up axial fused PET/CT (C) and CT (D) showed significantly decreased size of aforementioned lymph node, measuring about 3 mm (SUV$_{max}$ = 3.3). This case was recorded as true-positive according to size decrease > 30% after targeted therapy with minimum size change of 3 mm.

All patients gave written informed consent before the ^{18}F-rhPSMA-7 PET/CT imaging. All reported investigations were conducted in accordance with the Helsinki Declaration and with national regulations. The retrospective analysis was approved by the local ethics committee (permit 290/18S), and the requirement to obtain informed consent for data collection was waived. The administration of ^{18}F-rhPSMA-7 complied with The German Medicinal Products Act, AMG §13 2b, and the responsible regulatory body (Government of Oberbayern).

^{18}F-rhPSMA-7 PET/CT Imaging and Image Interpretation

^{18}F-rhPSMA-7 was synthesized and PET/CT scans were obtained as described previously (*11*). In brief, PET scans were acquired in 3-dimensional mode, together with intravenous and oral contrast-enhanced CT. The mean activity of ^{18}F-rhPSMA-7 was 331 MBq (IQR: 296–364 MBq), and the mean uptake time was 80 min (IQR: 67–89 min). Images were reviewed by an experienced, board-certified nuclear medicine physician and a board-certified radiologist. The Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were used for lesion assessment (*13*). All suspicious lesions were categorized into 4 regions (prostate bed, pelvic nodes, extrapelvic nodes/nonbone metastases, and bone metastasis), with a total of 21 subregions, using the miTNM framework (*13*).

Lesion Detection and Validation

DR was defined as the proportion of PSMA PET–positive patients to all patients independent of the reference standard, whereas the CDR was the percentage of patients who had at least 1 true PSMA PET–positive lesion localized that corresponded with a reference standard. The PPV was the proportion of patients who had true-positive findings divided by any positive.

The follow-up data, including proven histopathology (either by biopsy or surgery), imaging, or PSA follow-up after local/focal therapy, of all patients were reviewed. The combinations of above-mentioned follow-up data (priority in descending order) were defined as composite reference standard. The validated positive lesions in ^{18}F-rhPSMA-7 PET were recorded as true- or false-positive. True-negative was not defined.

Statistical Analysis

DRs were compared in each stratified PSA value subgroup using the Pearson χ^2 test with a 2-sided significance level of 0.05. True- and false-negative regions could not be determined because PET-negative regions were not be biopsied or followed up on, thus the specificity of the test could not be calculated. Statistical analysis was performed with MedCalc software (version 13.2.0, 2014; MedCalc).

TABLE 2
PPV and CDR of ^{18}F-rhPSMA-7 PET/CT

Validation	Total (*n*)	Confirmed (*n*)	Ruled-out (*n*)	PPV (%)*	CDR (%)
Composite					
PET-positive (per patient)	162	143	19	88 (95% CI, 82–92)*	70
PET-positive (per region)	210	157	53	75 (95% CI, 68–80)	
Histopathologic					
PET-positive (per patient)	22	20	2	91 (95% CI, 72–97)	73
PET-positive (per region)	23	20	3	87 (95% CI, 68–95)	

*Calculated using Wilson score method using asymptotic variance without continuity correction (in the study by Newcombe (*25*), method 3).

TABLE 3
CDR Stratified by PSA Level in Composite-Validated Subgroup

Stratification	No. of patients	No. of true-positive results (%)	No. of false-positive results (%)	DR (%)	PPV (%)	CDR (%)
PSA level (ng/mL) < 1	71	60 (85)	11 (15)	69	85	59
PSA level (ng/mL) ≥ 1	91	83 (91)	8 (9)	90	91	82

RESULTS

PPV and CDR

The DR of ^{18}F-rhPSMA-7 PET in the entire cohort was 80% (423/532 patients, Fig. 1). From all patients, 162 of 532 patients (30%) had follow-up after PET with a median duration of 5.6 mo (range: 1.1–14.2 mo). Most of these patients had follow-up based on imaging (115 patients, 71%), whereas 22 patients (14%) and 25 patients (15%) had histopathologic and PSA follow-up after targeted treatment, respectively. PSA follow-up was used as a part of the lesion validation in patients who received external-beam radiation as focal salvage therapy without systemic therapy. The detailed patients' characteristics and PSA response in this subgroup are shown in Supplemental Table 1 and Supplemental Figure 1 (supplemental materials are available at http://jnm.snmjournals.org), respectively. A patient example is shown in Figure 2.

In the composite-validated cohort, 143 of 162 patients (88%) had been validated as true-positive, resulting in a per-patient PPV of 88% (95% CI: 82%–92%). An example is shown in Supplemental Figure 2. On the basis of a DR of 80%, the estimated CDR in the composite-validated cohort was 70%. For the histopathologic-validated subgroup, the per-patient PPV was 91% (95% CI: 72%–97%), and the estimated CDR was 73%. PPVs according to a region-based analysis in both validated subgroups are demonstrated in Table 2.

In patients with PSA level ≥ 1 ng/mL DR, and PPV were 90% and 91%, respectively, resulting in a CDR of 82%. In patients with PSA level < 1 ng/mL, DR and PPV were 69% and 85%, respectively, resulting in a CDR of 59% (Table 3).

Discordant Results Between ^{18}F-rhPSMA-7 PET Positivity and Validation

From a total of 23 PET-positive lesions in the histopathology-validated cohort, 3 lesions (13%) were confirmed as non–PCa-related. These comprised 1 lesion in the prostate bed and 2 bone lesions. A ^{18}F-rhPSMA-7 PET-positive, but biopsy proven–negative bone lesion is shown in Figure 3. Eleven lesions were false-positive by imaging follow-up. These lesions were found in pelvic lymph nodes (6/11 regions, 55%), bone (1/11 regions, 9%), prostate bed (2/11 regions, 18%), and visceral organs (2/11 regions, 18%), as detailed in Supplemental Tables 2, 3, and 4. Eight lesions were nonevaluable (neither true- nor false-positive) and were excluded from the analysis (details in Supplemental Tables 5 and 6).

PET Disease Extent According to miTNM Staging

The miTNM stage by ^{18}F-rhPSMA-7 PET/CT is shown in Table 4. Localized disease (TrN0M0, T0N1M0, TrN1M0) was present in 43% of patients, who could be possible candidates for salvage treatment. M1 disease was present in 37% of patients. These patients evenly presented with or without locoregional disease (Tr/N1). Only a minority of these patients had a single type of distant metastases (M1a vs. M1b vs. M1c). Distribution of different miTNM stages was substantially different in the composite cohort (less Tr, more any M1 disease) given the approach to how lesions were validated.

Correlation of Lesion Detection Efficacy with Clinical Parameters

DR significantly increased with PSA value, with a DR of 58%, 87%, 85%, 93%, and 95% for PSA values of < 0.5 ng/mL, 0.5 ≤ 1.0 ng/mL, 1.0 ≤ 2.0 ng/mL, 2.0 ≤ 5.0 ng/mL, and ≥5.0 ng/mL, respectively (Fig. 4). ^{18}F-rhPSMA-7 PET/CT positivity


FIGURE 3. False-positive bone lesion on ^{18}F-rhPSMA-7 PET validated by histopathology. A 69-y-old man with BCR of PCa, Gleason score 7, post-RP with follow-up PSA value of 0.37 ng/mL. Sagittal CT (A) revealed sclerotic lesion at vertebral body and posterior element of C7, showing high ^{18}F-rhPSMA-7 uptake on sagittal ^{18}F-rhPSMA-7 PET (B) and sagittal fused PET/CT (C) with SUV$_{max}$ of 22.5. This lesion showed low signal intensity (SI) on sagittal T1-weighted MR image (MRI) (D), heterogeneous intermediate SI on sagittal T2-weighted MRI (E), with preservation of fatty marrow signal on sagittal fat-suppressed T1-weighted MRI (F). This pattern of signal intensity alteration probably corresponds to presence of hypervascularity and edema seen in early mixed active Paget disease. Biopsy at C7 was performed. Histopathologic specimen revealed reactive tissue without any PCa cells. Thorough workup of the biopsy sample definitely excluded a PCa metastasis but final diagnosis above general description of reactive tissue could not be established. Please note, that the biopsy may have the limitation in sampling errors, immunohistochemistry was not performed in this case, and it was decided to omit a rebiopsy given the unnecessary risk for patient.

TABLE 4
miTNM Stage by ^{18}F-rhPSMA-7 PET/CT

miTNM stage*	All patients (n = 532)		Efficacy cohort (n = 162)	
	n	%	n	%
M0				
T0N0M0	109	20	0	0
TrN0M0	117	22	20	12
T0N1M0	67	13	18	11
TrN1M0	43	8	4	2
M1				
T0N0M1	65	12	87	51
T0N1M1	67	13	18	11
TrN0M1	21	4	8	5
TrN1M1	43	8	7	4
Extrapelvic disease				
Any M1	196	37	120	71
M1a/c only	17	3	16	9
M1b only	38	7	90	53
Multiple				
Multiple regions	184	35	43	25

*miTNM stage in accordance with PROMISE (13).
Tr = prostate bed; N1 = pelvic nodes; M1 = extrapelvic disease.

significantly correlated with a post-RP PSA nadir of ≥ 0.1 ng/mL ($P = 0.005$). In contrast, PSA doubling time (dtPSA), Gleason score, TNM staging, and time from initial therapy to PSMA PET did not significantly correlate with PET DR, as shown in Table 5.

In the subgroup of patients ($n = 166$) with very low PSA (<0.5 ng/mL), 42% of the patients had a negative scan result. PSMA PET–positive lesions in this subgroup were mainly located exclusively in the prostate bed (45%). In the subgroup of patients ($n = 206$) with low PSA (PSA value from 0.5 to < 2.0 ng/mL), 47% of these patients had either local or regional pelvic node recurrence, whereas about one third of them (26% for PSA 0.5 to < 1.0 ng/mL, and 31% for PSA 1.0 to < 2.0 ng/mL) had recurrence in multiple regions.

The proportion of patients who had recurrence in multiple regions increased with rising PSA value, and notably when the PSA value increased above 2 ng/mL. The percentage of recurrence in multiple regions was 13%, 26%, 31%, 62%, and 69% for PSA values of <0.5 ng/mL, $0.5 \leq 1.0$ ng/mL, $1.0 \leq 2.0$ ng/mL, $2.0 \leq 5.0$ ng/mL, and ≥ 5.0 ng/mL, accordingly.

DISCUSSION

Our retrospective study aimed at exploring the PPV and CDR of ^{18}F-rhPSMA-7 PET/CT for the detection and localization of BCR in a large homogeneous population of patients after RP with a focus on lesion validation by histopathology or a composite standard of truth. Our results indicate that—similar to other PSMA-ligands for PET imaging—^{18}F-rhPSMA-7 is effective in detecting tumor lesions even at a low PSA value (14). In more than half of the patients, lesions could be detected even at low PSA values < 0.5 ng/mL.

The PPV of ^{18}F-rhPSMA-7 in a histopathology-validated cohort was similarly high (91%) when compared with other PSMA PET studies (ranges from 79% to 100%), summarized in a metaanalysis (6). However, composite validation delivered lower rates, indicating specific challenges especially for validation by follow-up imaging (e.g., insufficient size changes, lack of morphologic correlates from PSMA-ligand–positive lesions). The PPV of 88% confirmed by composite validation in our analysis was similar to data

FIGURE 4. Detection rate stratified by PSA levels.

TABLE 5
Detection Rate Stratified by PSA Level and Other Parameters on a Per-Patient Basis

Stratification	n	No. of PET-positive results (%)	$\chi 2$ P value
All patients	532	423 (80)	
PSA (ng/mL)			0.005
<0.5	166	96 (58)	
0.5 – <1.0	104	90 (87)	
1.0 – <2.0	102	87 (85)	
2.0 – <5.0	86	80 (93)	
≥5.0	74	70 (95)	
PSA doubling time (mo)			0.449
<6.8	59	49 (83)	
≥6.8	62	44 (71)	
Not available	411	330 (80)	
PSA nadir after prostatectomy (ng/mL)			<0.001
<0.1	135	103 (76)	
≥0.1	86	72 (84)	
Not available	311	248 (80)	
Time from initial therapy to PSMA PET (y)			0.785
<4.7	264	207 (78)	
≥4.7	267	215 (81)	
Not available	1	1 (100)	
Gleason score			0.483
≤7	155	119 (77)	
≥8	116	98 (84)	
Not available	261	206 (79)	
Primary T stage			0.555
≤T2	152	116 (76)	
≥T3	288	235 (82)	
Not available	92	72 (78)	

from a recent prospective phase III bicentric trial for ^{68}Ga-PSMA-11 (15) and early data reported for the CONDOR trial using ^{18}F-DCFPyL (84.8%–87.0% for 3 masked independent readers) (12,16). In principle, it is difficult to compare the PPV across different studies because of the different approaches used to validate lesions in the absence of histopathologic validation.

The CDR is a new term that aims to represent the detection efficacy of ^{18}F-rhPSMA-7 PET that was proven as true-positive by composite validation. To our knowledge, this retrospective study represents the first work to use CDR as an outcome parameter. The estimated CDR varied according to patients' PSA levels, ranging from 59% in patients with low PSA (<1 ng/mL), to 82% in patients with PSA ≥ 1 ng/mL. The results demonstrate that with both a lower DR and a lower PPV in lower PSA values, CDR as an outcome measurement currently investigated in phase III trials needs to be clearly adjusted to the patient population (CONDOR trial NCT03739684, and SPOTLIGHT trial NCT04186845).

The criteria and method of lesion validation play an important role in the CDR evaluation. In our study, most false-positive lesions validated by imaging follow-up were pelvic lymph nodes. Misinterpretation during imaging follow-up could occur for several reasons—most likely slow growth of recurrent tumor not fulfilling the prespecified validation criteria. False-positive lesions could be related to ganglia mimicking lymph nodes or PSMA-ligand uptake in reactive nodes (17,18). PSMA PET–positive bone lesions (designated as nonevaluable lesion on the basis of the applied criteria) are another source of difficult validation.

The DR of ^{18}F-rhPSMA-7 PET/CT increases with higher strata of PSA, similar to other PSMA PET tracers (6,8–10). ^{18}F-rhPSMA-7 has potential benefit over ^{68}Ga-PSMA tracers for restaging in patients with low PSA range (0.5 to < 1.0 ng/mL) as shown by the higher DR of ^{18}F-rhPSMA-7 compared with ^{68}Ga-PSMA studies (87% vs. 53% to 73%) (5,6,8,19–21), with comparably excellent results in patients with PSA values > 2 ng/mL. In our study, the PSA nadir significantly correlated with PSMA positivity, whereas the dtPSA did not. This is, for example, contrary to recent results for ^{68}Ga-PSMA-11 reported by Ceci et al. (22). Nevertheless, comparison between studies has several limitations such as the differing protocol and injected tracer activity. Thus, limited conclusions can be drawn.

A major limitation of the present work is related to the fact that no all-embracing composition validation was possible for all patients, given this study's retrospective nature. Thus, we can only

report an estimate of the CDR. A future prospective study with at least 1 lesion validation method for all patients is recommended.

CONCLUSION

^{18}F-rhPSMA-7 PET/CT offers high PPV in BCR after RP even in low PSA values. Its CDR is dependent on the prescan PSA value, with excellent CDR in patients with PSA $\geq$ 1 ng/mL, which is also related to limitations validating lesions in early recurrence.

DISCLOSURE

Matthias Eiber, Hans-Juergen Wester, and Alexander Wurzer have a patent application for rhPSMA. Matthias Eiber and Wolfgang Weber are consultants for Blue Earth Diagnostics (licensee for rhPSMA). Hans-Juergen Wester is founder, shareholder, and advisor board member of Scintomics GmbH, Fuerstenfeldbruck, Germany. No other potential conflict of interest relevant to this article was reported.

> ### KEY POINTS
>
> **QUESTION:** What is the overall DR, CDR, and PPV of ^{18}F-rhPSMA-7 PET/CT in BCR of PCa validated by composite reference standard?
>
> **PERTINENT FINDINGS:** This large cohort study revealed the overall DR of 80%. The PPV of ^{18}F-rhPSMA-7 PET/CT in composite and histopathology-proven cohorts was 88% and 91%, respectively. Thus, the CDRs in both subgroups were 70% and 73%, accordingly. There were higher DRs (90% vs. 69%), PPVs (91% vs.85%), and CDRs (82% vs. 59%) in the subgroup of patients with PSA level $\geq$ 1 ng/mL than in patients with PSA < 1 ng/mL. There was a significant positive correlation between ^{18}F-rhPSMA-7 PET/CT detection efficacy and stratified PSA levels ($P = 0.005$), as well as PSA nadir after prostatectomy ($P < 0.001$).
>
> **IMPLICATIONS FOR PATIENT CARE:** ^{18}F-rhPSMA-7 PET/CT offers high PPV in BCR after RP. Its CDR is dependent on the prescan PSA value, with excellent CDR in patients with a PSA level of $\geq$ 1 ng/mL.

REFERENCES

1. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. *JAMA.* 2008;299:2760–2769.
2. Mottet N, Bellmunt J, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. March 2018 update. European Association of Urology website. https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-large-text-V2.pdf. Accessed May 24, 2021.
3. Vargas HA, Martin-Malburet AG, Takeda T, et al. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: how much information can conventional imaging provide? *Urol Oncol.* 2016;34:482.e5–482.e10.
4. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. *Clin Nucl Med.* 2013;38:305–314.
5. Lawhn-Heath C, Flavell RR, Behr SC, et al. Single-center prospective evaluation of ^{68}Ga-PSMA-11 PET in biochemical recurrence of prostate cancer. *AJR.* 2019;213:266–274.
6. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of ^{68}Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. *J Nucl Med.* 2019;60:786–793.
7. Eissa A, Elsherbiny A, Coelho RF, et al. The role of ^{68}Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. *Minerva Urol Nefrol.* 2018;70:462–478.
8. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid ^{68}Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. *J Nucl Med.* 2015;56:668–674.
9. Mena E, Lindenberg ML, Turkbey IB, et al. ^{18}F-DCFPyL PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. *J Nucl Med.* 2020;61:881–889.
10. Giesel FL, Knorr K, Spohn F, et al. Detection efficacy of ^{18}F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. *J Nucl Med.* 2019;60:362–368.
11. Eiber M, Kroenke M, Wurzer A, et al. ^{18}F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. *J Nucl Med.* 2020;61:696–701.
12. Morris MJ, Pouliot F, Saperstein L, et al. A phase III, multicenter study to assess the diagnostic performance and clinical impact of ^{18}F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). *J Clin Oncol.* 2019;37(15, suppl):TPS5093.
13. Eiber M, Herrmann K, Calais J, et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. *J Nucl Med.* 2018;59:469–478.
14. Treglia G, Annunziata S, Pizzuto DA, Giovanella L, Prior JO, Ceriani L. Detection rate of ^{18}F-labeled PSMA PET/CT in biochemical recurrent prostate cancer: a systematic review and a meta-Analysis. *Cancers (Basel).* 2019;11:710.
15. Fendler WP, Calais J, Eiber M, et al. Assessment of ^{68}Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. *JAMA Oncol.* 2019;5:856–863.
16. Downs M. Progenics pharmaceuticals to announce and host a conference call to discuss top line results from Phase 3 CONDOR trial of PyL^{TM} in prostate cancer. Monday, December 23rd, 2019. globenewswire website https://www.globenewswire.com/news-release/2019/12/23/1964007/0/en/Progenics-Pharmaceuticals-Announces-Phase-3-CONDOR-Trial-of-PyL-in-Prostate-Cancer-Achieved-Primary-Endpoint.html. Accessed May 24, 2021.
17. Sheikhbahaei S, Werner RA, Solnes LB, et al. Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls. *Semin Nucl Med.* 2019;49:255–270.
18. Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. *Radiographics.* 2018;38:200–217.
19. Rauscher I, Duwel C, Haller B, et al. Efficacy, predictive factors, and prediction nomograms for ^{68}Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. *Eur Urol.* 2018;73:656–661.
20. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. ^{68}Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. *Eur Urol Focus.* 2018;4:686–693.
21. Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [^{68}Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. *Eur J Nucl Med Mol Imaging.* 2016;43:397–403.
22. Ceci F, Bianchi L, Borghesi M, et al. Prediction nomogram for ^{68}Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. *Eur J Nucl Med Mol Imaging.* 2020;47:136–146.
23. Bianchi L, Nini A, Bianchi M, et al. The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients. *EurUrol.* 2016;69:1142–1148.
24. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA.* 1999;281:1591–1597.
25. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. *Stat Med.* 1998;17:857–872.